The financing was co-led by Forbion and Corteva to accelerate the commercial rollout of disease-resistant banana varieties.
"This funding is a powerful endorsement of our team’s ability to bring breakthrough products to the hands of growers, exporters and consumers around the world. We are entering a new era, one where gene‑edited crops will significantly enhance food security and sustainability. 2025 proved that our technology delivers – not in the distant future, but right now. With two banana varieties already on the market and demand outstripping supply, this investment enables us to scale global production and expand into new crops faster than ever before. We are excited to be partnering with our new investors as we progress our mission to build a world-leading tropical seeds company."
The oversubscribed round was co-led by Forbion, FMC Ventures, and Corteva Inc.
"SOLASTA Bio has come a long way since we set out on this journey 3 years ago. Having established operations in the UK and US, we’ve now got an international team with outstanding competencies in technology and agribusiness and, importantly, we have developed our unique technology platform to address grower pain points. The results of our field trials have been hugely encouraging, demonstrating high efficacy of biopeptides against target insect pests, as effective or better than standard insecticides. With Series A now secured, it’s time for SOLASTA Bio to kick on to the next level and successfully hit our targets for commercialisation."